Abstract
Despite numerous studies investigating SARS-CoV-2 ACE2 binding affinity and its transmissibility, their relationship concerning varying immunity remains unclear. Daily ACE2 binding and immune escape in SARS-CoV-2 were calculated by summing the effects of all amino acid mutations in the receptor binding domain for each viral sequence per day, based on deep mutational scanning data. We developed an infectious disease transmission model that decomposed the effective reproduction number into viral infectiousness, host protection, and contact patterns. Viral infectiousness was used to represent a component of the fitness determined by both ACE2 binding and the immunity of infected hosts. By fitting the model to daily reported cases, immune escape, vaccine rollout, and population mobility, both viral infectiousness and effective immunity (i.e. the protection against the circulating variants) among infected individuals were quantified. A rugged fitness landscape, spanned by ACE2 binding and hosts’ effective immunity, was observed with peaks corresponding to individual VOCs (alpha, delta, and omicron (BA.1* and BA.2*)). We found that higher effective immunity was associated with a lower level of virus fitness peak initially; and lower effective immunity with weaker receptor binding was associated with an optimal virus fitness. The finding helps understand SARS-CoV-2 evolution and predict future dominant variants.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
City University of Hong Kong (#9610416 and #7005748) and General Research Fund (#9043514)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data and code availability
All data files and code scripts used in this study were uploaded to the GitHub website (https://github.com/DING219/bind_escape_code)
